We are analyzing https://link.springer.com/article/10.1007/s10549-004-1426-5.

Title:
Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma | Breast Cancer Research and Treatment
Description:
We have previously shown that the retinoid X receptor (RXR) ligand bexarotene (LGD1069, Targretin) is efficacious as a chemopreventive and chemotherapeutic agent in rat N-nitroso-N-methylurea (NMU)-induced mammary carcinomas (Cancer Res 58: 479–484, 1998). To determine additional role for bexarotene in breast cancer treatment, we evaluated the effect of bexarotene on the efficacy of paclitaxel (Taxol) treatment in a rat NMU-derived mammary tumor cell line, NMU-417,in vitro and in rat NMU-induced mammary tumors in vivo. Our growth inhibition results showed that the bexarotene/paclitaxel combination produced a concentration-dependent synergy in NMU-417 tumor cell line. Synergistic growth inhibition by the combination was associated with an increase in cell death induced by both agents. In rat NMU-induced mammary tumor model in vivo, the benefit of combination therapy was observed as early as 1 week after treatment and increased as treatment continued. At the end of 6 weeks of treatment, the bexarotene/paclitaxel combination produced an overall objective response rate of 94% compared with a rate of 12% in paclitaxel-treated and 58% in bexarotene-treated animals, an effect that was more than the additive effects produced by single agents. Although both bexarotene alone and the bexarotene/paclitaxel combination reduced tumor multiplicity to similar extent, the combination regimen produced a statistically significant decrease in total tumor burden compared to single agents and untreated controls (two-tailed, p > 0.05). Combination therapy did not further alter body weight nor increase toxicity when compared to single agents. In summary, our results demonstrated the potential of using a RXR selective ligand in combination with chemotherapy for the treatment of breast cancer.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,734,772 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

cancer, google, scholar, treatment, retinoid, mammary, combination, article, breast, lgd, lamph, res, ligand, bexarotene, taxol, paclitaxel, tumor, access, receptorselective, targretin, carcinoma, privacy, cookies, content, research, effect, cell, publish, search, synergistic, yen, receptor, rat, growth, produced, agents, chemotherapy, open, heyman, bischoff, data, information, log, journal, prudente, nmuinduced, results, bexarotenepaclitaxel, therapy, compared,

Topics {✒️}

rat n-nitroso-n-methylurea c-jun nh2-terminal kinase /extracellular signal-regulated kinase month download article/chapter molecular oncology receptor-selective ligand bexarotene preclinical models adipocyte-specific gene expression receptor-selective ligand lgd1069 related subjects bexarotene/paclitaxel combination produced concentration-dependent synergy phase ii trial mammary tumor regression privacy choices/manage cookies full article pdf induced gene expression receptor-selective retinoids active drug induced mammary carcinomas cell death induced metastatic breast cancer receptor-selective retinoid receptor access combination therapy rxr selective ligand rxr-selective ligand combination regimen produced mammary carcinoma published synergistic growth inhibition breast cancer treatment receptorselective ligand lgd1069 selective retinoid ligands european economic area november 2004 volume 88 determine additional role additive effects produced statistically significant decrease alter body weight structure-activity relationships clin oncology 19 synergistic cytotoxicity exhibited bexarotene-treated animals conditions privacy policy rxr-selective retinoid taxol-induced apoptosis article yen dose-effect relationships median-effect principle accepting optional cookies

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma
         description:We have previously shown that the retinoid X receptor (RXR) ligand bexarotene (LGD1069, Targretin) is efficacious as a chemopreventive and chemotherapeutic agent in rat N-nitroso-N-methylurea (NMU)-induced mammary carcinomas (Cancer Res 58: 479–484, 1998). To determine additional role for bexarotene in breast cancer treatment, we evaluated the effect of bexarotene on the efficacy of paclitaxel (Taxol) treatment in a rat NMU-derived mammary tumor cell line, NMU-417,in vitro and in rat NMU-induced mammary tumors in vivo. Our growth inhibition results showed that the bexarotene/paclitaxel combination produced a concentration-dependent synergy in NMU-417 tumor cell line. Synergistic growth inhibition by the combination was associated with an increase in cell death induced by both agents. In rat NMU-induced mammary tumor model in vivo, the benefit of combination therapy was observed as early as 1 week after treatment and increased as treatment continued. At the end of 6 weeks of treatment, the bexarotene/paclitaxel combination produced an overall objective response rate of 94% compared with a rate of 12% in paclitaxel-treated and 58% in bexarotene-treated animals, an effect that was more than the additive effects produced by single agents. Although both bexarotene alone and the bexarotene/paclitaxel combination reduced tumor multiplicity to similar extent, the combination regimen produced a statistically significant decrease in total tumor burden compared to single agents and untreated controls (two-tailed, p > 0.05). Combination therapy did not further alter body weight nor increase toxicity when compared to single agents. In summary, our results demonstrated the potential of using a RXR selective ligand in combination with chemotherapy for the treatment of breast cancer.
         datePublished:
         dateModified:
         pageStart:141
         pageEnd:148
         sameAs:https://doi.org/10.1007/s10549-004-1426-5
         keywords:
            bexarotene
            drug synergy
            mammary carcinoma
            paclitaxel
            retinoid X receptor
            Oncology
         image:
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:88
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Kluwer Academic Publishers
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Wan-ching Yen
               affiliation:
                     name:Ligand Pharmaceuticals Inc.
                     address:
                        name:Department of Molecular Oncology, Ligand Pharmaceuticals Inc., San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rene Y. Prudente
               affiliation:
                     name:Ligand Pharmaceuticals Inc.
                     address:
                        name:Department of Molecular Oncology, Ligand Pharmaceuticals Inc., San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:William W. Lamph
               affiliation:
                     name:Ligand Pharmaceuticals Inc.
                     address:
                        name:Department of Molecular Oncology, Ligand Pharmaceuticals Inc., San Diego, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma
      description:We have previously shown that the retinoid X receptor (RXR) ligand bexarotene (LGD1069, Targretin) is efficacious as a chemopreventive and chemotherapeutic agent in rat N-nitroso-N-methylurea (NMU)-induced mammary carcinomas (Cancer Res 58: 479–484, 1998). To determine additional role for bexarotene in breast cancer treatment, we evaluated the effect of bexarotene on the efficacy of paclitaxel (Taxol) treatment in a rat NMU-derived mammary tumor cell line, NMU-417,in vitro and in rat NMU-induced mammary tumors in vivo. Our growth inhibition results showed that the bexarotene/paclitaxel combination produced a concentration-dependent synergy in NMU-417 tumor cell line. Synergistic growth inhibition by the combination was associated with an increase in cell death induced by both agents. In rat NMU-induced mammary tumor model in vivo, the benefit of combination therapy was observed as early as 1 week after treatment and increased as treatment continued. At the end of 6 weeks of treatment, the bexarotene/paclitaxel combination produced an overall objective response rate of 94% compared with a rate of 12% in paclitaxel-treated and 58% in bexarotene-treated animals, an effect that was more than the additive effects produced by single agents. Although both bexarotene alone and the bexarotene/paclitaxel combination reduced tumor multiplicity to similar extent, the combination regimen produced a statistically significant decrease in total tumor burden compared to single agents and untreated controls (two-tailed, p > 0.05). Combination therapy did not further alter body weight nor increase toxicity when compared to single agents. In summary, our results demonstrated the potential of using a RXR selective ligand in combination with chemotherapy for the treatment of breast cancer.
      datePublished:
      dateModified:
      pageStart:141
      pageEnd:148
      sameAs:https://doi.org/10.1007/s10549-004-1426-5
      keywords:
         bexarotene
         drug synergy
         mammary carcinoma
         paclitaxel
         retinoid X receptor
         Oncology
      image:
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:88
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Kluwer Academic Publishers
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Wan-ching Yen
            affiliation:
                  name:Ligand Pharmaceuticals Inc.
                  address:
                     name:Department of Molecular Oncology, Ligand Pharmaceuticals Inc., San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rene Y. Prudente
            affiliation:
                  name:Ligand Pharmaceuticals Inc.
                  address:
                     name:Department of Molecular Oncology, Ligand Pharmaceuticals Inc., San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:William W. Lamph
            affiliation:
                  name:Ligand Pharmaceuticals Inc.
                  address:
                     name:Department of Molecular Oncology, Ligand Pharmaceuticals Inc., San Diego, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:88
Organization:
      name:Kluwer Academic Publishers
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Ligand Pharmaceuticals Inc.
      address:
         name:Department of Molecular Oncology, Ligand Pharmaceuticals Inc., San Diego, USA
         type:PostalAddress
      name:Ligand Pharmaceuticals Inc.
      address:
         name:Department of Molecular Oncology, Ligand Pharmaceuticals Inc., San Diego, USA
         type:PostalAddress
      name:Ligand Pharmaceuticals Inc.
      address:
         name:Department of Molecular Oncology, Ligand Pharmaceuticals Inc., San Diego, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Wan-ching Yen
      affiliation:
            name:Ligand Pharmaceuticals Inc.
            address:
               name:Department of Molecular Oncology, Ligand Pharmaceuticals Inc., San Diego, USA
               type:PostalAddress
            type:Organization
      name:Rene Y. Prudente
      affiliation:
            name:Ligand Pharmaceuticals Inc.
            address:
               name:Department of Molecular Oncology, Ligand Pharmaceuticals Inc., San Diego, USA
               type:PostalAddress
            type:Organization
      name:William W. Lamph
      affiliation:
            name:Ligand Pharmaceuticals Inc.
            address:
               name:Department of Molecular Oncology, Ligand Pharmaceuticals Inc., San Diego, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Molecular Oncology, Ligand Pharmaceuticals Inc., San Diego, USA
      name:Department of Molecular Oncology, Ligand Pharmaceuticals Inc., San Diego, USA
      name:Department of Molecular Oncology, Ligand Pharmaceuticals Inc., San Diego, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(50)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.07s.

LINK . SPRINGER . COM {}